We are excited to collaborate and work with ASC Therapeutics and the University of Massachusetts Medical School to develop a novel treatment for Maple Syrup Urine Disease (MSUD). Our goal is to “create new hope for patients and their families,” as stated by Dr. Kevin A. Strauss, Medical Director at CSC and collaborating clinical expert on the project. Our hope is that the project results in a safer, more effective precision therapy to treat MSUD.
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, today announced a partnership with the University of Massachusetts Medical School (UMMS) to co-develop a gene therapy for Maple Syrup Urine Disease (MSUD).
To read the full press release, please visit HERE.